EssexBio

Essex-Bio Group

简繁 EN

ANNOUNCEMENTS & SHAREHOLDER INFORMATION

Normative Disclosure, Honest Communication

Select category

ANNOUNCEMENTS SHAREHOLDER INFORMATION

Select time

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

Date

Title

File

Times

2023-04-18

NEXT DAY DISCLOSURE RETURN

1375

2023-04-17

NEXT DAY DISCLOSURE RETURN

1252

2023-04-04

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2023

1343

2023-03-29

FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 9 JUNE 2023 (or any adjournment thereof)

1338

2023-03-29

NOTICE OF ANNUAL GENERAL MEETING

1349

2023-03-29

PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS, ELECTION OF A NEW INDEPENDENT NON-EXECUTIVE DIRECTOR, TERMINATION OF THE EXISTING SHARE OPTION SCHEME, ADOPTION OF THE NEW SHARE OPTION SCHEME AND NOTICE OF ANNUAL GENERAL MEETING

1450

2023-03-27

NEXT DAY DISCLOSURE RETURN

1304

2023-03-21

NEXT DAY DISCLOSURE RETURN

1266

2023-03-20

NEXT DAY DISCLOSURE RETURN

1375

2023-03-17

NEXT DAY DISCLOSURE RETURN

1337

2023-03-16

NEXT DAY DISCLOSURE RETURN

1361

2023-03-15

NEXT DAY DISCLOSURE RETURN

1388

2023-03-14

NEXT DAY DISCLOSURE RETURN

1324

2023-03-13

NEXT DAY DISCLOSURE RETURN

1324

2023-03-08

FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2022

1321

2023-03-08

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2022

1353

2023-03-02

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2023

1349

2023-02-24

NOTICE OF BOARD MEETING

1288

2023-02-22

UPDATE ON DISCLOSEABLE TRANSACTION AMENDMENT AGREEMENT TO THE CO-DEVELOPMENT LICENSE AGREEMENT WITH SHANGHAI HENLIUS BIOTECH, INC. FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION

1318

2023-02-10

VOLUNTARY ANNOUNCEMENT FIRST PATIENT FIRST DOSE COMPLETED IN THE UNITED STATES IN AN INTERNATIONAL MULTI-CENTRE PHASE 3 CLINICAL STUDY IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS FOR THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

1398

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT